OP Asset Management Ltd Makes New Investment in Insulet Corporation $PODD

OP Asset Management Ltd acquired a new position in Insulet Corporation (NASDAQ:PODD) during the first quarter, according to its most recent 13F filing with the SEC. The firm acquired 7,211 shares of the medical instruments supplier’s stock, valued at approximately $1,513,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Banque Cantonale Vaudoise increased its position in Insulet by 68.3% during the 1st quarter. Banque Cantonale Vaudoise now owns 9,870 shares of the medical instruments supplier’s stock worth $2,071,000 after purchasing an additional 4,004 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in Insulet by 64.2% in the first quarter. Assenagon Asset Management S.A. now owns 257,719 shares of the medical instruments supplier’s stock valued at $54,080,000 after buying an additional 100,740 shares during the period. Krilogy Financial LLC acquired a new position in Insulet during the first quarter valued at approximately $243,000. PKO Investment Management Joint Stock Co grew its stake in Insulet by 25.0% during the first quarter. PKO Investment Management Joint Stock Co now owns 1,000 shares of the medical instruments supplier’s stock worth $210,000 after buying an additional 200 shares during the period. Finally, Brookstone Capital Management grew its stake in Insulet by 39.3% during the first quarter. Brookstone Capital Management now owns 3,499 shares of the medical instruments supplier’s stock worth $734,000 after buying an additional 988 shares during the period.

Insulet Price Performance

Shares of PODD stock opened at $157.74 on Tuesday. The firm has a fifty day simple moving average of $158.22 and a 200-day simple moving average of $219.15. The company has a market capitalization of $10.93 billion, a PE ratio of 36.68, a price-to-earnings-growth ratio of 1.10 and a beta of 1.13. Insulet Corporation has a twelve month low of $138.79 and a twelve month high of $354.88. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same quarter in the previous year, the firm posted $1.02 EPS. The firm’s quarterly revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities research analysts anticipate that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Insider Activity

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were acquired at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the transaction, the director owned 9,041 shares in the company, valued at $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.36% of the company’s stock.

Analysts Set New Price Targets

PODD has been the topic of a number of research reports. Stifel Nicolaus cut their target price on shares of Insulet from $350.00 to $250.00 in a research note on Thursday, May 7th. Evercore decreased their price target on shares of Insulet from $240.00 to $200.00 in a research report on Thursday, May 7th. JPMorgan Chase & Co. lowered their price target on Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a report on Thursday, May 7th. Wall Street Zen lowered Insulet from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Finally, Barclays decreased their target price on Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a research report on Thursday, May 7th. Twenty-two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $238.67.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.